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Abstract
Background: Antibodies towards placental-binding P. falciparum are thought to protect against pregnancy malaria;
however, environmental factors may affect antibody development. Methods and Findings: Using plasma from pregnant
Malawian women, we measured IgG against placental-binding P. falciparum parasites by flow cytometry, and related results
to intermittent preventive treatment (IPTp) regime, and bed net use. Bed net use was associated with decreased antibody
levels at mid-pregnancy but not at 1 month post partum (1 mpp). At 1 mpp a more intensive IPTp regime was associated
with decreased antibody levels in primigravidae, but not multigravidae.
Conclusions/Significance: Results suggest bed nets and IPTp regime influence acquisition of pregnancy-specific P.
falciparum immunity.
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Introduction
Plasmodium falciparum parasites that accumulate in the placenta
express unique variant surface antigens (VSA) including the
protein VAR2CSA, which enables the parasitised erythrocyte to
adhere to placental chondroitin sulphate-A (CSA) [1]. IgG
antibodies towards CSA-VSA (CSA-binding phenotype VSAs)
are gravidity dependent and have been associated with
protection from malaria-related low birth weight and maternal
anaemia [1]. The development of these antibodies may depend
on a combination of factors, including maternal genetics, HIV
status and parasite exposure, which in turn could vary with the
use of intermittent preventive treatment in pregnancy (IPTp) and
bed nets. Published data suggests IPTp may decrease CSA-VSA
IgG acquisition [2,3] and that this may be dependent on the
presence of HIV infection [2]. The effect of bed net use on
development of these antibodies is unknown. Antibody develop-
ment may be further affected by changes in transmission
intensity that decrease exposure to the antigen; and declines in
pregnancy malaria prevalence have been recently reported [4].
To examine the effect of bed nets and IPTp on CSA-VSA IgG
levels we measured antibody towards a CSA-binding parasite
line during pregnancy and post partum in pregnant Malawian
women participating in a randomised clinical trial of different
IPTp regimes.
Materials and Methods
Study population, sample and clinical data collection
The study population was a consecutive subset of women
(selected based on sample availability) from the Lungwena
Antenatal Intervention Study (LAIS) cohort (NIH registration
NCT00131235). Following written informed consent, pregnant
women at 14–26 gestation weeks (gw) were enrolled at an
antenatal clinic in Lungwena, Malawi, between December 2003
and October 2006. Women were randomly allocated to one of
three groups for IPTp treatment: sulfadoxine-pyrimethamine (SP)
(1500 mg/75 mg) twice during pregnancy; monthly SP from
enrolment, finishing before 37 gw; or azithromycin (AZI,
1000 mg) twice during pregnancy and monthly SP.
Parasitemia prevalence at enrolment and 28–34 gw was
determined by microscopy of Giemsa stained peripheral blood
smears. Maternal HIV status at enrolment was determined using
two rapid diagnostic tests (Determine, Abbot Laboratories, USA
and Uni-Gold, Trinity Biotech, Ireland). Bed net use, socioeco-
nomic status (maternal literacy and schooling) and gravidity were
determined using a questionnaire at enrolment. Serum separated
from venous or finger prick blood samples taken at enrolment and
1-month post partum (mpp) was frozen and shipped to Melbourne
for IgG measurement and analysis. Ethical approval was provided
by the Human Research Ethics Committee, Walter and Eliza Hall
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Hospital District in Finland, and the College of Medicine
Research and Ethics Committee, University of Malawi.
P. falciparum line
Parasitised red blood cells (PRBC) infected with P. falciparum line
CS2, which binds CSA and expresses var2csa, were cultured [5] in
RPMI-HEPES medium with 0.2% w/vol NaHCO3 and 0.5%
Albumax II (GIBCO
TM) in Group-O red blood cells (RBC)(Aus-
tralian Red Cross Blood Service).
Measurement of IgG
Flow cytometry was used to measure IgG levels to VSA on the
PRBC (CSA-VSA IgG), as described previously [5]. Heat
inactivated human sera (1:20 dilution; in duplicate) were co-
incubated with 4–8% trophozoite stage PRBC at 0.1% haema-
tocrit in PBS with 1% neonatal calf serum, with polyclonal rabbit
anti-human IgG antibody (1:100, DakoCytomation, Denmark)
and with AlexafluorH 488 donkey anti-rabbit IgG (1:500,
Invitrogen, USA) with 10 mg/ml ethidium bromide (EtBr). A
relative geometric mean fluorescence intensity (relative MFI) for
PRBC was calculated using negative (unexposed adults) and
positive (pooled serum with high CSA-VSA IgG) controls.
Data analysis
Data were analysed using Stata (Version9, Stata Corp., USA).
CSA-VSA IgG levels (relative MFI) were log transformed prior to
regression analysis. Unless otherwise stated results are for
multivariate analysis with relative MFI at enrolment and 1 mpp
defined as outcome variables, and bed net use, IPTp regime, HIV
status, gravidity (primi-, secundi- or multigravidae) and parasit-
emia defined as exposure variables. P values of ,0.05 were taken
as significant.
Results
CSA-VSA IgG was measured in 538 women at enrolment (14–
26 gw) and 364 women at 1 mpp; 355 women had samples
assayed at both time points. CSA-VSA IgG at enrolment and
1 mpp was positively associated with gravidity (Table 1). The
mean (SD) age of the participants was 24.9 (6.7) years. Neither
participants’ age, gravidity, HIV nor socioeconomic status varied
significantly with bed net use or IPTp regime; bed net use and
ITN regime were also not associated with each other.
At enrolment, bed net use (prevalence 63%) and HIV infection
(prevalence 14%) were associated with lower CSA-VSA IgG.
Concurrent P. falciparumparasitemia (prevalence9%) wasassociated
witha non-significantlyhigherCSA-VSA IgGlevel (Table 1).When
the data were stratified by gravidity, there was a significant negative
association between bed net use and CSA-VSA IgG at enrolment
in primigravidae (coefficient 20.672; 95%CI 21.245, 20.099,
P=0.022), but not in multigravidae (coefficient 20.307; 95% CI
20.632, 0.018 P=0.064) or secundigravidae (coefficient 20.588;
95% CI 21.442, 0.266 P=0.18). HIV infection was associated with
non-significantly lower CSA-VSA IgG at enrolment in primigrav-
idae (coefficient;20.709 95% CI 21.869, 0.276 P=0.14) and
multigravidae (coefficient 20.404; 95% 20.826, 0.016 P=0.059)
but not secundigravidae (coefficient 20.060; 95% 21.237, 1.118
P=0.92).
At 1 mpp, among all women tested, levels of CSA-VSA IgG
were non-significantly lower in women who received SP+AZI
compared to women who received two-dose SP (Table 1), and
CSA-VSA IgG levels in women who received monthly SP were
intermediate (compared to the other two regimes). When stratified
by gravidity, there were significantly lower levels in primigravidae
who received SP+AZI than those who received two-dose SP
(coefficient 21.447; 95% CI 22.800, 20.094 P=0.036); levels in
primigravidae who received monthly SP were intermediate
(coefficient 21.189; 95% CI 22.613, 0.233 P=0.1) (Figure 1A).
Secundigravidae who received SP+AZI had non-significantly
lower levels compared two-dose SP (coefficient 20.989; 95% CI
22.213, 0.235 P=0.11); and similar levels to secundigravidae who
received monthly SP (coefficient 20.371; 95% CI 21.634, 0.893
P=0.56). In contrast to primigravidae, multigravidae who
received two-dose SP had similar CSA-VSA IgG levels to those
who had monthly SP (coefficient 20.088; 95% CI 20.729, 0.552
P=0.79) and to those who had received SP+AZI (coefficient
0.118; 95% CI 20.495, 0.731 P=0.71) (Figure 1B).
Because HIV infection has been associated with decreased
antibody response to IPTp, we assessed whether the relationships
Table 1. Association between specified factors and IgG to CS2-VSA, multivariate analysis.
Enrolment 1 month post partum
n (%) Co-efficient (95%CI) P n (%) Co-efficient (95%CI) P
Gravidity primigravidae 129 (24.0) 81 (22.3)
secundigravidae 107 (19.9) 0.402 (20.014, 0.818) 0.058 77 (21.2) 0.805 (0.139, 1.472) 0.018
multigravidae 302 (56.1) 1.335 (0.996, 1.673) ,0.001 206 (56.6) 1.627 (1.063, 2.191) ,0.001
HIV
1 negative 400 (74.3) 279 (76.6)
positive 66 (12.3) 20.395 (20.783, 20.006) 0.047 35 (9.6) 20.291 (20.988, 0.405) 0.41
unknown 72 (13.4) 50 (13.7)
ITN
1 negative 200 (37.2) 139 (38.2)
positive 338 (62.8) 20.449 (20.728, 20.171) 0.002 225 (61.8) 20.251 (20.699, 0.197) 0.27
Parasitemia
2 negative 492 (91.5) 331 (90.9)
positive 46 (8.6) 0.469 (20.019, 0.957) 0.060 33 (9.1) 20.391 (21.159, 0.362) 0.30
Treatment
3 Two-dose SP 118 (32.6)
monthly SP 115 (31.6) 20.352 (20.889, 0.184) 0.20
monthly-SP+AZI 131 (36.0) 20.366 (20.882, 0.150) 0.16
doi:10.1371/journal.pone.0029874.t001
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were also seen in HIV negative women. Among HIV negative
women who received SP+AZI, only primigravidae had signifi-
cantly lower CSA-VSA IgG than those who received two-dose SP
(coefficient-1.400; 95%CI 22.769- 20.032, P=0.045). HIV
negative women who used bed nets had significantly lower CSA-
VSA IgG at enrolment compared to those who did not use bed
nets (coefficient 20.501; 95%CI 20.802, 20.200, P=0.001), and
this did not appear to be explained by differences in schooling or
literacy (data not shown). Due to the low HIV prevalence, HIV
positive women were not separately assessed for the effects of IPTp
regime or bed net use on antibody levels.
Discussion
We examined the association between CSA-VSA IgG antibod-
ies and use of bed nets and IPTp in the context of a randomised
clinical trial in pregnant women. We found that bed net use and
intensive IPTp regimes were associated with lower levels of these
antibodies. These associations were not dependent on the presence
of HIV infection, but the association between IPTp regime and
antibody was clearly dependent on gravidity. At antenatal
booking, antibody levels were lower in women who used bed nets
or who were HIV positive. At 1 mpp the most intensive IPTp
regime was associated with decreased antibody in primigravidae.
The observation that the difference was between the SP+AZI and
two-dose SP regimes, not two-dose SP and monthly SP regimes,
suggests that it is the drug AZI which accounts for the lower CSA-
VSA IgG levels. Interestingly, a high frequency (90%) of mutations
associated with SP resistance has been found in P. falciparum
infections in Malawi [6].
That bed net use is associated with decreased antibody is a novel
finding, and may indicate that bed nets decreased exposure to
CSA-binding parasites before antenatal clinic attendance. Where-
as most antimalarial drugs are not recommended in the first
trimester, using bed nets from conception may decrease parasite
exposure in early pregnancy. We found that bed net use was not
associated with antibody at 1 mpp, while the monthly SP+AZI
regime was, suggesting that intensive IPTp, which may both clear
existing infection and inhibit new infection, may be a more
important determinant than bed net use of the development of
antibody in the latter part of pregnancy.
Previous studies have yielded conflicting findings on the
relationship between IPTp and pregnancy-specific immunity
[2,3]. Staalsoe et al showed that CSA-VSA IgG levels were
decreased among primigravidae receiving SP over placebo. In
Mozambique, women of all gravidities did not show decreased
CSA-VSA IgG with two doses of SP-IPTp, unless they were HIV
positive [2]. HIV infected women may require more than two
doses of SP to be protected from pregnancy malaria [7]. In the
present study, the association between IPTp and antibody
development was not restricted to HIV positive women.
Differences between studies may be due to variation in SP
resistance, both Mozambique and Malawi have SP resistant
parasites [8,9]. Given the recommendation that all pregnant
women in areas like Lungwena receive IPTp [10], we had no
placebo group. Instead, we observed a clear relationship between
more intensive IPTp regimes and antibody levels in primigravidae,
suggesting that the more intensive regimes decrease exposure to
the antigen, decreasing antibody development. In keeping with
this, we observed a lower prevalence of P. falciparum infection
(detected by microscopy of Giemsa stained peripheral blood
smears) at 32 weeks and at delivery in women receiving monthly
SP 6 AZI (2% at each time point) than in women receiving two-
dose SP (5% at each time point) [6]. Parasite prevalence at
delivery estimated by quantitative PCR was also significantly
higher in women receiving two-dose SP (Luntamo et al, in
preparation).
The observation that IPTp use was only associated with
antibody levels in primigravidae may reflect higher existing levels
of immunity in multigravidae, such that decreased antigen
exposure with intensive IPTp regimes had minimal effects on
immunity. The protective effect of IPTp may also be more modest
in women with existing immunity, and these women, usually
multigravidae, may be more capable of boosting antibody levels
[5] in response to sub microscopic infections, which were relatively
common [11].
At enrolment, history of bed net use was associated with
decreased antibody in both primigravidae and multigravidae,
although the association only reached statistical significance in
primigravidae. By contrast, IPTp regime was only associated with
antibody level at delivery in primigravidae. This difference in
associations between bed nets and IPTp with antibody may be due
to the total time that the intervention can decrease antigen
exposure (as bed net use might reflect decreased exposure over a
prolonged period, not just the current pregnancy), or to the ability
of bed nets to block boosting of antibodies by infection in early
pregnancy.
Our study had a number of potential shortcomings. The low
prevalence of HIV and parasitemia compromised our ability to
Figure 1. Relationship between antibody to CS2 variant surface antigens and IPTp regime, stratified by gravidity.
doi:10.1371/journal.pone.0029874.g001
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measured antibody at two time points during pregnancy, but
antibody levels may rapidly decrease following clearance of
infection, and are in any case highly dynamic [5]. Being a
community based study, it was usually not possible to document
placental infection and as peripheral parasitemia was measured by
microscopy [11] and at limited time points, parasitaemia
prevalence was likely underestimated. (Only a subset of women
in the present study also contributed to the comparison of qPCR
and microscopy). In choosing samples from a sequential set of
women for this study, the probability of selection bias was
minimised, and the LAIS used population based sampling [6].
Socioeconomic factors that could indicate altered risk of P.
falciparum exposure, potentially compromising analyses, were not
associated with HIV or bed net use. We could, of course, only
determine statistical associations, not causal relationships, between
interventions and antibody development.
If bed nets and intensive IPTp decrease pregnancy-specific
immunity, this may have important implications for the ongoing
susceptibility of pregnant women to malaria. As coverage with bed
nets and IPTp rises, more women may receive their benefits, but
they may be increasingly vulnerable in subsequent pregnancies.
The only study that examined this found that chemoprophylaxis in
the third trimester did not affect malaria susceptibility in the
subsequent pregnancy, but participants may have already
experienced substantial exposure and developed immunity by this
time [12]. If bed nets and IPTp cease to be widely available, many
highly-susceptible pregnant women could be again exposed to
high risk of pregnancy malaria, with potentially devastating
consequences. Whether the relationships between bed nets and
IPTp use and development of immunity are similar in higher
transmission settings, is currently unknown. The effects of
decreased exposure and decreased antibody on susceptibility to
disease need to be properly addressed by longitudinal studies over
successive pregnancies.
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